Robert Mancini, PharmD, BCOP, FHOPA is the Oncology/Pharmacy Program Coordinator at St. Luke's Cancer Institute (SLCI) in Boise, ID. Robert started his career working in the realm of oral chemotherapy where he helped start the SLCI Oral Chemotherapy Program about 15 years ago. He went on to serve in multiple additional roles within the Cancer Institute, serving as the pharmacist-in-charge at the Fruitland chemo infusion center, as an oncology supportive care pharmacist as part of an NCCCP grant through the Cancer Institute, helping establish the supportive care clinic model.

In 2017, he transitioned to become the first BMT pharmacist and Program Coordinator within the Cancer Institute where he helped establish the allogeneic stem cell transplant program, which is the first and only program in the state of Idaho. In 2022, he went on to also help establish the first and only CAR-T program in the state of Idaho. Since then, he has expanded to assist with program development for specialty areas such as Precision Medicine, Cardio-Oncology, and Supportive Care pharmacist roles.

He has also served as the PGY2 Oncology Residency Program Director since 2012, having overseen the development of more than 30 PGY2 Oncology Residents. Since 2016, Robert has also served as an adjunct clinical instructor overseeing the oncology therapeutics module at Idaho State University, including starting a special topics oncology elective in 2018. Robert was recognized with the HOPA New Practitioner Award in 2014, selected as Fellow of HOPA in 2020, and received the HOPA Oncology Pharmacy Leadership Award in 2023.

Robert earned his PharmD from the University of California San Diego and completed a PGY1 Hospital Pharmacy Residency at St. Luke's Health System and a PGY2 at St. Luke's Mountain States Tumor Institute (now referred to as SLCI). He has been board certified in oncology since 2012. His research interests include BMT, cellular therapies, and oncology pharmacy education.